Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKinsey
Colorcon
Mallinckrodt
Express Scripts

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,747,020

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 6,747,020 protect, and when does it expire?

Patent 6,747,020 protects INSPRA and is included in one NDA.

Protection for INSPRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in twenty-seven countries.

Summary for Patent: 6,747,020
Title: Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor
Abstract:Methods of using eplerenone, an angiotensin converting enzyme inhibitor and optionally a diuretic are described for treatment of heart failure and hypertension.
Inventor(s): Perez; Alfonzo T. (Lake Forest, IL), Asner; Debra J. (Morton Grove, IL), LaChapelle; Richard J. (Wilmette, IL), Alexander; John C. (Princeton, NJ), Roniker; Barbara (Chicago, IL)
Assignee: Pharmacia Corporation (St. Louis, MO)
Application Number:10/077,134
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,747,020

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,747,020

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 021106   Start Trial
Argentina 029155   Start Trial
Austria 249242   Start Trial
Austria 310537   Start Trial
Australia 1714000   Start Trial
Australia 2005201045   Start Trial
Australia 3394500   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Johnson and Johnson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.